<?xml version="1.0" encoding="UTF-8"?>
<p>Inhibitors of HO activity are metalloporphyrins, which do not carry an iron molecule but are replaced by tin, chromium, or zinc, inhibit the rate limiting enzyme heme oxygenase [
 <xref rid="B9-antioxidants-09-00636" ref-type="bibr">9</xref>,
 <xref rid="B10-antioxidants-09-00636" ref-type="bibr">10</xref>,
 <xref rid="B11-antioxidants-09-00636" ref-type="bibr">11</xref>,
 <xref rid="B12-antioxidants-09-00636" ref-type="bibr">12</xref>,
 <xref rid="B13-antioxidants-09-00636" ref-type="bibr">13</xref>,
 <xref rid="B14-antioxidants-09-00636" ref-type="bibr">14</xref>,
 <xref rid="B15-antioxidants-09-00636" ref-type="bibr">15</xref>]. Tin (Sn
 <sup>4+</sup>) has been used to lower bilirubin levels in newborns to treat hyperbilirubinemia in newborns [
 <xref rid="B6-antioxidants-09-00636" ref-type="bibr">6</xref>]. HO-1 cleaves the tetrapyrrole ring at the methylene bridge to produce carbon monoxide (CO) biliverdin, and iron [
 <xref rid="B6-antioxidants-09-00636" ref-type="bibr">6</xref>,
 <xref rid="B16-antioxidants-09-00636" ref-type="bibr">16</xref>]. Biliverdin is reduced to bilirubin by biliverdin reductase in mammals. Since COVID-19 binds porphyrin and removes iron and oxygen to form a COVID-19-Porphyrin complex, it can behave as a metalloporphyrin and competitively inhibits HO-1 (
 <xref ref-type="fig" rid="antioxidants-09-00636-f003">Figure 3</xref>) [
 <xref rid="B17-antioxidants-09-00636" ref-type="bibr">17</xref>].
</p>
